Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Biochip Array Analyzer Detects Colorectal Cancer-Related Polymorphisms

By HospiMedica International staff writers
Posted on 15 Sep 2008
A diagnostic test can detect 28 polymorphisms associated with colorectal cancer (CRC) in a single stool sample.

The test, called RanplexCRC, does not require a hospital visit or dietary restrictions and is more sensitive than the currently used fecal occult blood (FOB) -screening test. More...
It accurately profiles patients and reduces the number of patients for colonoscopy, saving time and resources and reducing patient discomfort.

Developed by Randox (Crumlin, UK), the test identifies selected mutations present in four genes: APC, KRAS, BRAF, and Tp53, along with wild-type control sequences. These mutations are represented on two biochips and are detected using Randox' biochip array analyzers.

The biochip array analyzers are immunoassay-testing platforms that work by combining panels of related tests on a single biochip. The chemiluminescent endpoint is detected by a charge-coupled device (CCD) camera and quantified by custom image-processing software. The company markets Evidence, a fully automated analyzer for high-throughput laboratories, and the Evidence Investigator, a semi-automated analyzer for low-throughput laboratories.

Most sporadic colorectal cancers follow a well-recognized progression from normal cells through adenoma (abnormal glandular growths) to cancer, driven by mutations in a small number of genes. CRC is the second largest cause of cancer mortality in the western world, but up to 90% are curable if detected early. Unfortunately, most patients present with advanced disease, reducing their long-term survival.

National screening programs are being introduced throughout Europe, to reduce CRC mortality, using the FOB test. This test suffers from poor sensitivity, as not all tumors bleed (false-negative test) and not all stool-blood are derived from tumors (false-positive test). Therefore, many patients (up to 50%) may be sent for colonoscopies unnecessarily. RanplexCRC provides the answer, filtering out false-positives.

Randox is a diagnostics company that develops, manufactures, and markets clinical diagnostic products worldwide. Core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; environmental diagnostics; and recombinant proteins and antibodies.

Related Links:

Randox


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.